OBJECTIVE  To explore the application of the “CMO-PC”(capacity-motivation-opportunity-pharmaceutical care) model in the reproductive pharmacy outpatient clinic.

METHODS  The “CMO-PC” model was utilized to establish a clinical practice framework “patient stratification assessment, implementation of pharmaceutical care actions, and utilization of remote pharmaceutical care to inspire patient adherence through collaborative management” for patients attending the reproductive pharmacy outpatient clinic at author’s hospital. A retrospective analysis was conducted on consultation cases.

RESULTS  From July 2023 to June 2024, a total of 350 patient consultations were managed using the “CMO-PC” model, representing a 43.0% increase compared with the same period of the previous year. Patient records were established for 163 cases(46.6%). A stratification model was used to assess high-risk factors, with 42 cases(12.00%) classified as prioridad 1, 95 cases(27.14%) as prioridad 2, and 213 cases(60.86%) as prioridad 3. A total of 497 pharmaceutical care actions were implemented, including 16 instances(8.12%) of providing preconception medication consultations and guidance; 185 instances(37.22%) of reorganizing medications used outside the hospital prior to the treatment cycle and assessing their impact on fertility; 27 instances(5.43%) of individualized protocol development for patients undergoing ovarian stimulation after the treatment cycle; 124 instances(24.95%) of medication guidance for down-regulating agents, ovarian stimulation medications, ovulation-inducing agents, and luteal support medications; 127 instances(25.55%) of conducting risk assessments for teratogenicity of medications and exposure to environmental factors before and after embryo transfer; 11 instances(2.21%) of selecting treatment plans for special diseases after pregnancy; and 7 instances(1.41%) of identifying and managing adverse drug reactions related to assisted reproductive medication. Remote pharmaceutical care were provided to patients 19 times through WeChat, phone calls.

CONCLUSION As a novel pharmaceutical care model, the “CMO-PC” model can serve as an important supplement to outpatient pharmaceutical care, helping to enhance the effectiveness of these services and providing new insights for national pharmaceutical care reform.